Tag: Biotech
The novel vaccine delivery devices market is projected to grow at an annualized rate of ~20% - Roots Analysis
Roots Analysis has done a detailed study on “Novel Vaccine Delivery Devices Market, 2019-2030” covering key aspects of the industry’s evolution and identifying potential future growth opportunities.
The novel vaccine delivery devices market - Roots Analysis
Owning to a variety of relevant reasons, which include trypanophobia and dependence on the cold chain, there is an evident demand for innovative and user-friendly vaccine delivery systems that are also safe and efficient
The patient recruitment and retention services market - "Roots Analysis"
Roots Analysis has done a detailed study on Patient Recruitment and Retention Services Marker, 2019-2030.” https://www.rootsanalysis.com/reports/view_document/patient-recruitment-and-retention-services-market-2019-2030/245.html For more information, p...
Patient Recruitment and Retention Services, 2019-2030 - RootsAnalysis
A detailed assessmentof the current market landscape, including information on drug developer(s
Patient Recruitment and Retention Services Marker
A steadily increasing demand for study participants and the complexities associated with patient enrollment has imposed a significant burden on drug developer companies
The cell therapy manufacturing market - "Roots Analysis"
Manufacturing cell therapies is technically and financially demanding; as a result, despite therapy developers gradually strengthening their in-house expertise, they are also becoming increasingly reliant on contract service providers
The patient recruitment and retention services market - RootsAnalysis
Roots Analysis has done a detailed study on Patient Recruitment and Retention Services Marker, 2019-2030.”, covering key aspects of the industry’s evolution and identifying potential future growth opportunities.
The cell therapy manufacturing market is estimated to reach close to USD 11 Billion - "Roots Analysis"
The approval of KYMIRAH®, YESCARTA®, Alofisel® and Zyntelgo® has increased the interest of pharma stakeholders in cell therapies; further, owing to the technical challenges in this field, outsourcing manufacturing operations has become a necessity
companies claim to be actively engaged in offering patient recruitment / retention services to the medical devices industries- "Roots Analysis"
Roots Analysis has done a detailed study on Patient Recruitment and Retention Services Marker, 2019-2030.”, covering key aspects of the industry’s evolution and identifying potential future growth opportunities.
The patient recruitment and retention services market- Rootsanalysis
A steadily increasing demand for participants in clinical research studies, coupled to the complexities associated with patient enrolment, have prompted drug / therapy developers to outsource this process to specialty service providers
More than 100 industry players and over 60 non-industry players currently
Owing to various reasons, the demand for cell therapies is anticipated to increase over the coming years.
Growing at an annualized rate of over 16.5%
Theapproval of KYMIRAH®, YESCARTA®, Alofisel® and Zyntelgo® has increased theinterest of pharma stakeholders in cell therapies; further, owing to thetechnical challenges in this field, outsourcing manufacturing operations hasbecome a necessity
The cell therapy manufacturing market is projected to grow
Owing to various reasons, the demand for cell therapies is anticipated to increase over the coming years. Therefore, both therapy developers and contract service providers may need to strengthen their capabilities and expand available capacity.
The cell therapy manufacturing market is estimated - RootsAnalysis
Manufacturing cell therapies is technically and financially demanding; as a result, despite therapy developers gradually strengthening their in-house expertise, they are also becoming increasingly reliant on contract service providers.
the cell therapy manufacturing market is estimated
The approval of KYMIRAH®, YESCARTA®, Alofisel® and Zyntelgo® has increased the interest of pharma stakeholders in cell therapies.
